Generation and characterization of interferon-lambda 1-resistant H1N1 influenza A viruses

PLoS One. 2017 Jul 27;12(7):e0181999. doi: 10.1371/journal.pone.0181999. eCollection 2017.

Abstract

Influenza A viruses pose a constant potential threat to human health. In view of the innate antiviral activity of interferons (IFNs) and their potential use as anti-influenza agents, it is important to know whether viral resistance to these antiviral proteins can arise. To examine the likelihood of emergence of IFN-λ1-resistant H1N1 variants, we serially passaged the A/California/04/09 (H1N1) strain in a human lung epithelial cell line (Calu-3) in the presence of increasing concentrations of recombinant IFN-λ1 protein. To monitor changes associated with adaptation of this virus to growth in Calu-3 cells, we also passaged the wild-type virus in the absence of IFN-λ1. Under IFN-λ1 selective pressure, the parental virus developed two neuraminidase (NA) mutations, S79L and K331N, which significantly reduced NA enzyme activity (↓1.4-fold) and sensitivity to IFN-λ1 (↓˃20-fold), respectively. These changes were not associated with a reduction in viral replication levels. Mutants carrying either K331N alone or S79L and K331N together induced weaker phosphorylation of IFN regulatory factor 3 (IRF3), and, as a consequence, much lower expression of the IFN genes (IFNB1, IFNL1 and IFNL2/3) and proteins (IFN-λ1 and IFN-λ2/3). The lower levels of IFN expression correlated with weaker induction of tyrosine-phosphorylated STAT1 and reduced RIG-I protein levels. Our findings demonstrate that influenza viruses can develop increased resistance to the antiviral activity of type III interferons.

MeSH terms

  • Amino Acid Substitution / genetics
  • Animals
  • Antiviral Agents / pharmacology
  • Cell Line
  • DEAD Box Protein 58 / metabolism
  • DNA-Directed RNA Polymerases / metabolism
  • Dogs
  • Drug Resistance, Viral / drug effects*
  • Enzyme-Linked Immunosorbent Assay
  • Gene Expression Regulation / drug effects
  • Humans
  • Immunity, Innate / drug effects
  • Influenza A Virus, H1N1 Subtype / drug effects
  • Influenza A Virus, H1N1 Subtype / genetics*
  • Influenza A Virus, H1N1 Subtype / growth & development
  • Influenza A Virus, H1N1 Subtype / physiology*
  • Interferon Regulatory Factor-3 / metabolism
  • Interferons
  • Interleukins / pharmacology*
  • Mutation / genetics
  • Neuraminidase / genetics
  • Phosphorylation / drug effects
  • Receptors, Immunologic
  • Receptors, Virus / genetics
  • Recombination, Genetic / genetics
  • STAT1 Transcription Factor / metabolism
  • Sequence Analysis, DNA
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • interferon-lambda, human
  • IRF3 protein, human
  • Interferon Regulatory Factor-3
  • Interleukins
  • Receptors, Immunologic
  • Receptors, Virus
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • Interferons
  • DNA-Directed RNA Polymerases
  • Neuraminidase
  • RIGI protein, human
  • DEAD Box Protein 58

Grants and funding

This study was supported by Grant No. 2011094 from the FDA Medical Countermeasures Initiative program to RPD, by an RAS Presidium Grant in Molecular and Cell Biology to NVB, and by a Senior Postgraduate Research Fellowship Award to NAI from the Oak Ridge Institute for Science and Education.